Board of Directors
Marco Chacón, PhD
Founder and Chairman, Paragon Bioservices
Paragon was founded by Dr. Chacón in 1990 and has continued to develop and grow under his leadership as a translational Center of Excellence for the development and GMP manufacturing of biopharmaceuticals—including therapeutic proteins and vaccines.
Dr. Chacón’s research interests include the control of metabolism, oxygen homeostasis and regenerative medicine. In 2000, these scientific interests crystallized with the formation of Irazú BioDiscovery, LLC, a technology development company targeting the induction of hypoxia tolerance and neuroprotection—as observed in caloric restriction models, the developing mammal and hibernating species.
Marco received a BS degree in Biology from Youngstown State University and a Ph.D. in Nutritional Sciences from the University of Maryland, College Park. His many awards include: two Industry Executive Awards from Pharma Voice magazine (“The Entrepreneur” and “100 Most Inspiring People” awards, in 2011 and 2013. He serves on the Executive Committee of the Technology Council of Maryland (MD Bio division) and is a Member of the Board of Trustees for the University of Maryland, Baltimore Foundation (UMB). In late 2015, Dr Chacon was appointed by Governor Lawrence J. Hogan , Jr. as a member of the “Maryland Life Sciences Advisory Board”.
Partner, NewSpring CapitalDr. Ratnam is a Partner at NewSpring Capital, where she focuses on the healthcare sector, covering technology-enabled services (including healthcare IT), pharmaceutical services and specialty pharmaceuticals (particularly, generics and post-approval products). Her prior experience is in drug discovery and development, as well as enabling biotechnologies. She has a PhD from The Ohio State University and completed her postdoctoral training at the University of Pennsylvania. Dr. Ratnam also has an MBA from Columbia University.
Donald W. Hughes
Patner & CFO, Camden Partners
Don joined Camden Partners in 1997 and is a Partner and the Chief Financial Officer. He has over 30 years of experience working with and advising small public and private companies. Don serves as a resource to portfolio companies in the areas of accounting, financial reporting, information systems and recruiting, among others. He serves or has served on the boards of AgilQuest, Inc., BioMedical Enterprises, Inc., Calvert Education Services, Inc., Centene Corporation (observer), Collections Marketing Center, Inc. (observer), IncentOne, Inc., MinSec Holdings, Inc., New Horizons Worldwide, Inc., Occupational Health + Rehabilitation Inc., Questar Assessment, Inc., Santa Rosa Consulting, Inc., and Towne Park, Inc. (observer) all of which are current or former Camden Partners’ portfolio companies.
Previously, Don served as Chief Financial Officer of Capstone Pharmacy Services, Inc., a public, small-cap institutional pharmacy services provider. He also spent 12 years as Executive Vice President and Chief Financial Officer of Broventure Company, Inc., a closely-held investment company and family office, and 11 years in the audit division of Arthur Andersen LLP. Don has also previously served on the boards of several public and private growth companies, as well as, several not-for-profit groups, including the Board of the Maryland Food Bank. He is currently serving on the board of trustees for Lycoming College.
Don earned a B.A. degree from Lycoming College, an M.S.F. degree from Loyola University Maryland and is a Certified Public Accountant.
President and Chief Executive Officer, Paragon Bioservices
Peter Buzy brings over 25 years of executive management experience to Paragon, primarily in the areas of finance and biotechnology. Pete initially joined Paragon as Chief Operating Officer in 2014 and later was assigned the responsibility of President. Pete currently holds the position of Chief Executive Officer and is an active member on Paragon’s board of directors. Prior to Paragon, he spent over 13 years as a senior executive at Martek Biosciences Corporation (NASDAQ: MATK), a leader in the innovation, development, production and sale of high-value products from microbial sources. He played a key role in developing Martek’s business from an R&D company to a fully integrated and profitable commercial organization with over $470M in annual sales. While serving as Executive Vice President and Chief Financial Officer at Martek, Pete successfully raised over $300M in both private and public financing. He successfully oversaw several large corporate acquisitions, collaborations and licensing arrangements, cultivating company growth while setting the stage for Martek’s sale to Royal DSM NV in 2011 for close to $1.1B. He also earned the 2011 CFO of the Year from the Technology Council of Maryland.
Additionally, his career includes a 13-year tenure with Ernst & Young, where he was admitted to partnership in the Northern Virginia High Technology and Life Science Practice as Audit Partner serving a variety of private and publicly traded biotechnology companies. Pete received a Bachelor of Business Administration, Accounting, from Salisbury University in Maryland and he also serves on the Board and Executive Committees of the Technology Council of Maryland.
Principal, Intralytix, Inc.Mr. Hervy is an entrepreneur and experienced CEO of small to large corporations. Following his MBA from the Wharton School, University of Pennsylvania, in 1974, he joined Thomson, SA, and became the President and CEO of Thomson CGR Medical Corporation. In 1985, Mr. Hervy acquired Sopha Medical Systems, Inc., a nuclear medicine company. As Sopha’s Chairman and CEO, Mr. Hervy executed a successful turn around and growth plan by the time he sold it in 1988. Mr. Hervy also served as a founding trustee of the Maryland Venture Capital Trust and currently serves as chairman of MDBio, Inc., and a trustee of St. Mary’s College of Maryland.
Principal, Robert Roche Associates LLC
Mr. Roche is the founding member of Robert Roche Associates LLC, a consulting firm providing guidance to the pharmaceutical and healthcare industries. He created this firm upon his retirement from Cephalon Inc., in February 2010.
He joined Cephalon in January 1995 as the Vice President of Sales and Marketing and was named Executive Vice President, Worldwide Pharmaceutical Operations in 2005. Before joining Cephalon, Mr. Roche served as Director and Vice President, Worldwide Strategic Product Development, for SmithKline Beecham’s central nervous system and gastrointestinal products business. He also was managing director of SmithKline’s pharmaceutical operations in the Philippines. Prior to that, he held senior marketing positions in Canada and Spain and had product planning responsibilities for SmithKline in Latin America. Mr. Roche began his pharmaceutical career in 1982 with SmithKline & French as a U.S. pharmaceutical sales representative.
Mr. Roche is a member of the boards of directors of Aratana Therapeutics of Kansas City, KS, and Antares Pharmaceuticals of Ewing, NJ. He formerly served as a director of LiceCell, Inc., up until its acquisition in 2008, EKR Therapeutics, until its acquisition in 2012, Civitas Therapeutics of Chelsea, MA, and NuPathe, Inc., of Conshohocken, PA, until they were acquired in 2014. He also serves on the board of Bryn Mawr Hospital. He is a graduate of Colgate University and earned an MBA from The Wharton School at the University of Pennsylvania.